ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-7.25278.9
Cost of Revenue---
Gross Profit-7.25278.9
Operating Expenses
Research Development22,806.10716,784.6267,445.669
Selling General and Administrative10,016.9026,430.2525,364.39
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-32,823.009-23,207.628-12,531.159
Income from Continuing Operations
Total Other Income/Expenses Net810.705-208.4227.352
Earnings Before Interest and Taxes-32,012.304-23,416.05-12,523.807
Interest Expense---
Income Before Tax-32,012.304-23,416.05-12,523.807
Income Tax Expense--27.54327.543
Minority Interest---
Net Income From Continuing Ops-32,012.304-23,388.507-12,551.35
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-32,012.304-23,388.507-12,551.35
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-32,012.304-23,388.507-12,551.35